Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacodynamics 100%
• Cytokine 100%
• Mouse 50%
• Mouse Mutant 50%
• Drug 50%
• Tumor Necrosis Factor 50%
• Lipopolysaccharide 50%
• Protein Kinases 50%

Neuroscience

• Mitogen-Activated Protein Kinase 100%
• In Vivo 33%
• Proinflammatory Cytokine 33%
• Brain 33%
• Protein Kinases 16%
• Glia 16%
• Lipopolysaccharide 16%
• CXCL1 16%
• Cytokine Production 16%